American journal of ophthalmology
-
To review what progress has been made towards the application of ocular gene therapy to prevent progressive vision loss in patients affected by choroideremia. ⋯ Whereas the time frame for the development of therapies for some retinal dystrophies may be in the years hence, gene therapy trials for choroideremia have started in the United Kingdom and results are pending. These first trials may help resolve the remaining issues associated with the treatment of this disease.
-
Randomized Controlled Trial Comparative Study
A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema.
To compare visual acuity and spectral-domain optical coherence tomography (SDOCT) outcomes associated with intravitreal (IV) bevacizumab vs IV ranibizumab for the management of diabetic macular edema (DME). ⋯ IV bevacizumab and IV ranibizumab are associated with similar effects on central subfield thickness in patients with DME through 1 year of follow-up. IV ranibizumab is associated with greater improvement in BCVA at some study visits, and the mean number of injections is higher in the IV bevacizumab group.